Biomarkers for Breast Adenocarcinoma Using In Silico Approaches

Author:

Pandi Jhansi1,Arulprakasam Ajucarmelprecilla1ORCID,Dhandapani Ranjithkumar2ORCID,Ramanathan Saikishore1,Thangavelu Sathiamoorthi1,Chinnappan Jayaprakash3,Vidhya Rajalakshmi V.3,Alghamdi Saad4ORCID,Shesha Nashwa Talaat5,Prasath S.6ORCID

Affiliation:

1. Medical Microbiology Unit, Department of Microbiology, Alagappa University, Karaikudi, Tamil Nadu, India

2. Chimertech Private Limited, Chennai, India

3. Department of Bioinformatics, Bharathiar University, Coimbatore, Tamil Nadu, India

4. Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia

5. Hera General Hospital, Directorate of Health Affairs, Makkah, Saudi Arabia

6. Department of Mechanical Engineering, College of Engineering and Technology, Mizan Tepi University, Ethiopia

Abstract

This work elucidates the idea of finding probable critical genes linked to breast adenocarcinoma. In this study, the GEO database gene expression profile data set (GSE70951) was retrieved to look for genes that were expressed variably across breast adenocarcinoma samples and healthy tissue samples. The genes were confirmed to be part of the PPI network for breast cancer pathogenesis and prognosis. In Cytoscape, the CytoHubba module was used to discover the hub genes. For correlation analysis, the predictive biomarker of these hub genes, as well as GEPIA, was used. A total of 155 (85 upregulated genes and 70 downregulated genes) were identified. By integrating the PPI and CytoHubba data, the major key/hub genes were selected from the results. The KM plotter is employed to find the prognosis of those major pivot genes, and the outcome shows worse prognosis in breast adenocarcinoma patients. Further experimental validation will show the predicted expression levels of those hub genes. The overall result of our study gives the consequences for the identification of a critical gene to ease the molecular targeting therapy for breast adenocarcinoma. It could be used as a prognostic biomarker and could lead to therapy options for breast adenocarcinoma.

Publisher

Hindawi Limited

Subject

Complementary and alternative medicine

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3